Navigation Links
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Date:1/14/2008

NUTLEY, N.J., Jan. 14 /PRNewswire/ -- Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with ribavirin as the market-leading treatment for patients with hepatitis C, in the United States and globally. Despite clear biases in the design of the "IDEAL" study that potentially favored patients taking Peg-Intron(TM) (peginterferon alfa-2b) regimens - particularly the ribavirin dose reduction protocol - the study results have shown that patients treated with a PEGASYS regimen had a similar chance of being successfully treated for hepatitis C.

"I do not expect that the results of the IDEAL study will meaningfully impact clinical practice, except to inform physicians on the appropriate dosing of Peg-Intron and to reinforce the already widely-accepted view that optimizing ribavirin dosing throughout treatment is critical to achieving success and preventing treatment relapse in hepatitis C," said Douglas Dieterich, M.D., Professor of Medicine in the Division of Hepatology at Mt. Sinai School of Medicine in New York, New York.

In 2001, the U.S. Food and Drug Administration (FDA) required Schering- Plough to conduct a post approval commitment trial to determine if a lower dose of Peg-Intron (1.0 mcg/kg) was as effective as the approved dose of 1.5 mcg/kg, both in combination with identical ribavirin regimens. A third arm was added to the study in which patients received PEGASYS 180 mcg with a different ribavirin dosing schedule. This mismatch of ribavirin dosing introduces several potential biases into the study because experts agree that an optimized dose of ribavirin, with either pegylated interferon, is critical to achieving success in hepatitis C treatment. In particular, maintaining a full dose of ribavirin has shown an important ability to reduce relapse following the end of treatment.

"PEGASYS quickly became the market leader after its launch, based on robust cli
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
2. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
3. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
4. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
11. Schering-Plough Reports Top-Line Results of the IDEAL Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... July 19, 2011 The U.S. Food and Drug ... proposed oversight approach for certain mobile applications specific to ... that are designed for use on smartphones and other ... new apps, focuses only on a select group of ...
... Biomerix Corporation and Gel Company today announced a strategic ... novel three-dimensional tissue scaffold. Under the agreement, Gel Company ... researchers in the life science community across the United ... a non-degradable, open-cell  polycarbonate polyurethane , designed to mimic ...
Cached Medicine Technology:FDA Outlines Oversight of Mobile Medical Applications 2Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... 22, 2015 A new white paper ... and person-centeredness in the long-term care environment as well ... the continuum. The paper, “The Power of Person-Centeredness in ... and practices of the patient, resident and family experience ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the main ... , Auto insurance quotes help many drivers find the ... to call an agent or visit an agency for price ... website: http://autocarinsurancebest.com/ . , Every business who relies heavily ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... 8 (HealthDay News) -- New research finds older U.S. women ... women, suggesting that older patients may not be benefiting as ... past three decades. Researchers analyzed U.S. government data from ... were stable throughout the 1980s for women aged 20-64 but ...
... published in the online version of the Journal of ... edition of the journal. The JCO is the peer-reviewed publication ... leading professional society representing physicians who treat people with cancer. ... in the US. Over 100,000 patients are diagnosed each year ...
... women are more likely than their male counterparts to suffer ... new national study led by George Mason University researcher Lisa ... smoke and be victimized, the research finds. "Why?" Lindley ... theories. "Bisexuals are often invisible," she says of bisexual women. ...
... Reporter , MONDAY, Nov. 7 (HealthDay News) -- The U.S. ... on cigarette packs was derailed temporarily Monday when a federal ... the tobacco industry,s First Amendment free-speech rights. Judge ... of Columbia said it was likely that the tobacco industry ...
... of its kind, scientists from Toronto,s Centre for Addiction and Mental ... higher risk of developing schizophrenia. This finding was based on a ... a group that did not use drugs, but also to heavy ... online on Nov. 8, 2011, at AJP in Advance, ...
... with breast cancer lag behind younger women diagnosed with the ... on improvements in treatment and detection, according to new research ... The study, published in the Journal of Clinical Oncology ... improvements made in breast cancer outcomes over the past three ...
Cached Medicine News:Health News:Advances in Breast Cancer Care May Not Be Reaching Older Women 2Health News:Northern Ireland company makes major breakthrough in cancer treatment 2Health News:Bisexual women, more likely than bisexual men, to be depressed and abuse alcohol, new study finds 2Health News:Judge Blocks FDA Plan for Graphic Cigarette Warnings 2Health News:Judge Blocks FDA Plan for Graphic Cigarette Warnings 3Health News:CAMH study suggests increased risk of schizophrenia in heavy methamphetamine users 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 2Health News:UT MD Anderson study finds advances in breast cancer don't extend to older women 3
... Tests are qualitative immunoassays for detecting elevated levels ... is fast and results are easy to interpret. ... darker than the control band, then ovulation will ... If the test band does not appear or ...
Detect LH surge for predicting ovulation, Able to detect as low as 40 mIU/mL LH or 30 mIU/mL LH, Simple, easy and accurate, Built-in control system...
... The Clinitek® 50 analyzer ... offering physician offices and ... and consistency of state-of-the-art ... better, more efficient way ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: